"Liquid biopsy" has been introduced for the analysis of circulating tumor cells (CTCs) in the blood of cancer patients, and this new diagnostic approach has received enormous attention. CTCs are derived from primary tumors and metastatic lesions and, therefore, harbor important information on the molecular characteristics relevant to tumor progression and cancer therapy. Analyses of CTCs have paved new diagnostic avenues with obvious clinical implications for personalized medicine. Key areas of clinical applications of CTCs include detection of cancer, prediction of prognosis in patients with curable disease, monitoring systemic therapies, and stratification of patients based on the detection of therapeutic targets or resistance mechanisms. The present Review will focus on the current knowledge derived from single-cell analysis of CTCs at the DNA, RNA, and protein level and emphasize the unique opportunities for performing functional studies that aim to identify the metastasis-initiator cells in cancer patients and obtain predictive information for steering cancer therapies.
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Keywords: biomarkers; cancer; cancer therapy; circulating tumor cells; liquid biopsy; molecular characterization; tumor biology Liquid biopsy has been originally introduced for the analysis of circulating tumor cells (CTCs) and includes now circulating cell-free DNA (cfDNA), cell-free microRNAs, exosomes, oncosomes, and blood platelets. Technologies that detect very small amounts of CTCs have been developed and validated in clinical studies [1] .
Liquid biopsy analyses provide interesting information on molecular features of tumor lesions used to contribute to early detection of small primary and metastatic lesions and personalized management of cancer patients including the determination of prognosis, stratification of patients to targeted therapies, realtime monitoring of therapy efficacy, and identification of therapy targets and resistance mechanisms [1] . Moreover, CTCs are biomarkers with a biological function in metastatic development, and their analyses might have the potential to reveal important key mechanisms of cancer progression [2] .
Abbreviations ALK-reaR, anaplastic lymphoma kinase-rearrangement; APC, adenomatous polyposis coli; BRCA, breast cancer; CfDNA, cell-free DNA; CTC, circulating tumor cell; EGFR, epithelial growth factor receptor; ER, estrogen receptor; FGF2, fibroblast growth factor; ISH, in situ hybridization; MBC, metastatic breast cancer; PD-L1, programmed death-ligand 1; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PSA, prostate-specific antigen; PSMA, prostate-specific membrane antigen; ROS1-reaR, ROS1-rearrangement; TMPRSS2-ERG, transmembrane protease, serine 2 (TMPRSS2)-v-ets erythroblastosis virus E26 oncogene homolog (ERG).
Methods for enrichment and detection of CTCs have been described and extensively discussed elsewhere [3] . Briefly, CTCs are enriched based on their biological and physical differences from the surrounding blood cells. In patients with epithelial tumors, EpCAM-based enrichment of CTCs is the current gold standard, however, new ways of CTC enrichment are currently evaluated to assess the level of EpCAM (À) tumor cells in blood [2] . For CTC detection, antibodies to cytokeratins are the current standard. Again, additional markers directed against cancer cells with reduced cytokeratin expression are currently assessed for specificity and clinical relevance [2] . Different types of CTC characterization studies have been carried out: (a) descriptive studies on isolated individual CTCs requiring a specific isolation process (e.g., DEPArray) and a process of whole genome or transcriptome amplification [4, 5] , which are informative on intrapatient heterogeneity; (b) descriptive studies providing information at the individual cell level, which require only an enrichment but no single-cell isolation (e.g., multiple immunostaining, qRT-PCR, FISH, or EPISPOT); (c) functional studies on pools of total CTCs used for cell culture and/or xenografts.
The current review will focus on the characterization of single CTCs at the DNA, RNA, and protein level ( Fig. 1 ) and emphasize the ability to perform functional in vitro and vivo studies on CTCs obtained from patients with breast, colon, lung, and prostate cancer as the main entities in Europe and the United States.
Genomic aberrations

Technology aspects
To reveal genomic aberrations, single CTCs are identified by immunostaining and are subsequently analyzed by either FISH analyses or they are isolated manually [6] or automatically [7] and the DNA is amplified by WGA procedures [5, 8] . After WGA, the DNA can be analyzed for Copy Number Aberrations and specific mutations using Next Generation Sequencing technologies [9] . It should be noted that WGA can induce artifacts and the results need to be therefore carefully validated [5, 8] .
Clinical studies
Mutations in genes encoding therapeutic targets or signaling proteins downstream of the target can affect the efficacy of targeted drugs (Fig. 2) .
Mutations in epithelial growth factor receptor (EGFR) affect outcome of anti-EGFR therapies in lung cancer. Activating aberrations such as the L858R mutation (exon 21) and the deletion in exon 19 in the tyrosine kinase domain of EGFR are predictive biomarkers of sensitivity to erlotinib and gefinitib while the T790M (exon 20) confers drug resistance to these drugs.
In metastatic non-small-cell lung cancer, EGFRactivating mutation was identified in CTCs [10] . T790M mutation was revealed in CTCs from patients who had received tyrosine kinase inhibitors. Serial increase in CTC counts was associated with tumor progression, with the emergence of additional EGFR mutations in some cases.
Mutations in KRAS-a protein downstream of EGFR-block the efficacy of anti-EGFR therapy in colorectal cancer. Recently, the analysis of hundreds of CTCs obtained from colorectal cancer patients revealed a high intra-and interpatient heterogeneity of KRAS [6, 11] . CTCs with mutated KRAS genes will escape anti-EGFR therapy and their early detection might help to guide therapy in individual patients. In colorectal cancer, screening for druggable mutations in CTCs [4] revealed mutations in known driver genes DNA mRNA Intra-cytoplasmic proteins
Membrane proteins
Secreted, shed and released proteins GENOME TRANSCRIPTOME PROTEOME [e.g., adenomatous polyposis coli (APC), KRAS, or phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)] in the primary tumor and metastasis as well as the corresponding CTCs of the same patients. Interestingly, some CTCs revealed a high level of amplification of CDK8 as potential new therapeutic target for CDK inhibitors [4] . Mutations in the AR gene were identified in CTCenriched peripheral blood samples from patients with castration-resistant prostate cancer [12] . AR amplifications enable the tumor cells to profit from the minute amounts of residual androgens in patients receiving drug-induced castration therapy, while AR mutations can result in tumor cells that are refractory to androgen blockade.
Resistance against HER2-targeting therapies involves activation of the PI3 kinase pathway, for example, by mutations in the PIK3CA gene in breast cancer (BRCA). PIK3CA mutations were revealed in enriched CTC pools of 15.9% of metastatic breast cancer (MBC) patients [13] . Analysis of isolated single CTCs resulted in higher detection rates of PIK3CA mutations and showed strong intrapatient heterogeneity in the PIK3CA mutational status [14] [15] [16] .
Moreover, mutations in the gene coding for the estrogen receptor (ER), ESR1, have been associated with acquired endocrine resistance in patients with ER-positive MBC [17] . Functional studies revealed that these ESR1 mutations lead to constitutive activity of the ER, meaning that the receptor is active in the absence of its ligand estrogen, conferring resistance against several endocrine agents. Genomic analysis of single CTCs should result in the detection of emerging clones harboring ESR1 mutations as it has already been shown in circulating-free DNA in MBC patients pretreated with endocrine therapy [18] . In melanomas, targeted therapies have started to change the dismal prognosis of metastatic disease. BRAF has become one of the lead targets for therapy with specific inhibitors, and mutations in the BRAF gene are important predictors of sensitivity to therapy, although resistance occurs rapidly in most treated patients. Recently, dynamic changes in BRAF mutations were detected in CTCs [19, 20] , which may guide BRAF-directed therapies in the future.
Besides the detection of specific mutations, CTCs offer an ideal option to characterize genomic abnormalities in CTCs from anaplastic lymphoma kinaserearranged (ALK-reaR) NSCLC patients. Using a new semiautomated microscopy of filtration-enriched CTCs [21] , Pailler et al. [22] provided the first proof-of-concept that ALK-rearrangement can be detected in CTCs of patients with ALK-rearranged NSCLC. CTCs from these patients harbor a unique ALK break-apart rearrangement, including patients presenting another form of rearrangement in the biopsy, and these CTCs had a mesenchymal phenotype. Moreover, it was possible to detect ROS1-rearrangement (ROS1-reaR) in CTCs [23] . These are examples how CTC characterization performed under treatment could help to stratify patients at risk of early resistance to crizotinib.
Finally, transmembrane protease, serine 2 (TMPRSS2)-v-ets erythroblastosis virus E26 oncogene homolog (ERG; TMPRSS2-ERG) fusion, an androgen-dependent growth factor has been studied in CTCs as a biomarker of sensitivity to abiraterone acetate in prostate cancer [24, 25] .
RNA
Technology aspects
For RNA analyses, three technical strategies have been used so far. First, CTCs are enriched by several logunits and the resulting fraction, which usually still contains thousands of leukocytes, has been analyzed by RT-PCR for cancer-associated transcript (e.g.,, PSA in prostate cancer [26] and CK19 in BRCA [27] ). However, careful control studies need to be performed to demonstrate that the transcriptome profile is derived from CTCs. Secondly, CTCs are isolated in a way that preserves RNA stability, and the transcriptome profile of these cells are determined by multiplex RT-qPCR [28] or RNA sequencing [29] . Thirdly, in situ hybridization with probes against specific transcripts can be employed to single CTCs, which allows to assess the heterogeneity between individual CTCs in the same patient and also reveals information on cell morphology and immunostaining patterns. However, it is restricted usually to a few probes per cell.
Clinical studies
Recent studies focusing on prostate cancer also demonstrated that mRNA analysis of CTCs could reveal substantial information on drug sensitivity and resistance. For example, mRNA expression of AR-V7, a truncated form of androgen receptor (AR) that lacks the ligand-binding domain but remains constitutively active, in CTCs could predict failure of antiandrogen therapy with enzalutamide and abiraterone [30, 31] (Fig. 2) . AR-V7-positive patients may retain sensitivity to chemotherapy [32] [33] [34] [35] , and AR-V7 is therefore currently evaluated as a treatment-selection marker in metastatic prostate cancer. Besides AR-V7, additional mechanisms of resistance have been revealed by RNA sequencing of CTCs [36] .
In addition, noncoding RNAs are key regulators of gene expression. Recently, a robust in situ hybridization (ISH) protocol, enabling clinical investigation of important miRNAs, such as miR-10b on a cell-by-cell basis, and providing proof-of-principle data in breast, prostate, and colorectal cancer patients, has been developed [37] .
Proteins
Technology aspects
Protein analyses on single CTCs are currently performed by immunostaining with antibodies directed against protein of interest. Multiple labeling is possible but usually restricted to a few proteins of interest for tumor cell biology and cancer therapy. More advanced cell proteomics methods have not been employed for CTCs so far, probably due to the low yield of CTCs in most cancer patients. The further development of these methods is of utmost importance to obtain indepth insights into the protein signature of single CTCs. This may help to identify signaling pathways relevant to metastasis development and treatment responses.
Clinical studies
The ER is the most prominent therapeutic target in BRCA expressed in 70-80% of primary tumors. Patients with ER-positive breast carcinomas receive endocrine therapy (cutoff: 1% of immunostained tumor cells) but they can harbor ER-negative CTCs [38, 39] , which might be a potential mechanism of resistance currently evaluated in clinical trials.
Another target, the HER2 oncogene, is amplified and overexpressed in approx. 20% of primary breast carcinomas and has become another key target also expressed in other tumor entities. Although primary tumors are currently used to stratify patients to HER2-directed therapy, overt distant metastases and CTCs have discrepant HER2 statuses compared to the primary tumor in up to 30% of cases [40] . Current multicenter trials evaluate now if the presence of HER2-positive CTCs in patients with HER2-negative primary tumors can be used as novel stratification criterion [41, 42] .
More recently, immune checkpoint regulators such as programmed death-ligand 1 (PD-L1) have become exciting new therapeutic targets leading to long-lasting remissions in patients with advanced malignancies [43] . First evidence was presented that PD-L1 is frequently expressed on CTCs (> 60% of patients) in MBC patients [44] . The established CTC/PD-L1 assay can be used for liquid biopsy in future clinical trials on patients undergoing immune checkpoint blockade.
In prostate cancer, prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) are upregulated following AR activation and AR suppression, respectively. Interestingly, PSA/PSMA-based measurements on CTCs appear to be surrogates for AR signaling in CTCs, and this information might help to predict the outcome of AR-based therapy [45] .
Functional studies
Technology aspects
A prerequisite for functional analyses was the recent advances in our ability to culture CTCs in vitro or expand CTCs in vivo using xenografts. For short-term cell culture and the detection of viable CTCs, the EPI-SPOT technology has been developed and validated in clinical studies [46] . For an unbiased enrichment of viable CTCs, leukocyte depletion is used. The detection of only viable CTCs is based on their secretion or release of cancer-associated proteins (e.g.,, PSA for prostate cancer, HER2 for BRCA).
It should be not noted that both establishment of CTC lines and xenografts require hundreds of CTCs in the blood sample which are usually found only in patients with very advanced disease. An exception might be small-cell lung cancer patients, which harbor on average ten times more CTCs than patients with any other solid tumor entities [47] . This requirement of high CTC loads is not surprising because even if CD44 high CD24 low BRCA stem cells are used it requires hundreds of cells to establish a xenograft [48] . Patient-derived xenografts have become a valuable tool in cancer research [49] . However, their use for personalized medicine is very limited due to the fact that it takes many months to obtain a tumor and the success rate is not high.
Unfortunately, several reports on the establishment of functional CTC models lacked information on the success rate (i.e., how many samples were cultured to obtain the reported cell lines or xenografts). For example, for the establishment of the first CTC line in colon cancer, 165 blood samples from unselected patients needed to be cultured [50] . Thus, new approaches have to be developed that allow significantly increasing the capture of CTCs [51, 52] .
Clinical studies
The first colon CTC line from single CTCs with stem cell properties has been described in 2015 [50] . This CTC line designated 'CTC-MCC-41' is in culture for 4 years. Importantly, this thorough analysis showed that CTC-MCC-41 cells resemble characteristics of the original tumor cells in the colon cancer patient and display a stable phenotype characterized by an intermediate epithelial/mesenchymal phenotype, stem celllike properties, and an osteomimetic signature indicating a bone marrow origin. Functional studies showed that CTC-MCC-41 cells induced rapidly in vitro endothelial cell tube formation and in vivo tumors after xenografting in immunodeficient mice. More recent results highlighted that CTC-MCC-41 cells display a very specific transcription program including key genes related to energy metabolism, DNA repair and stemness genes were observed [53] . Such data may supply insights for the discovery of new biomarkers to identify the most aggressive CTC subpopulations and for the development of new drugs to inhibit metastasis-initiator CTCs in colon cancer.
In BRCA, primary cultures from CTCs of BRCA patients with brain metastases [54] and oligoclonal cultures (sustained in vitro for > 6 months) of CTCs isolated from 6 patients with metastatic disease [55] have been employed. In prostate cancer, a 3D organoid system and a long-term culture from the peripheral blood of one patient with castration-resistant metastatic disease have been used [56] . In lung cancer, Nagrath and coworkers have developed an in situ capture and culture methodology for in vitro expansion of CTCs using a 3D coculture model [57] .
In addition, in the first xenograft model, CTCs from patients with metastatic luminal BRCA were injected into the tibial bone of immunodeficient mice and gave rise to bone, lung and liver metastases [58] . These metastases uniformly expressed EpCAM, CD44, CD47, and MET, which might be important for engraftment and metastatic outgrowth of CTCs. In a subsequent validation cohort, the number of EpCAM (+) CD44
(+) CD47 (+) MET (+) CTCs correlated with increased number of metastatic sites and poor prognosis.
The most established cell culture assay detecting viable CTCs at the single-cell level is the EPISPOT assay (EPithelial Immuno-SPOT assay) [46, 59] . It has been used on hundreds of patients with different tumor types (e.g., breast, prostate, colon cancer) and allows the detection of viable clinically relevant CTCs. In BRCA, CTCs were identified by the secretion of the release of CK19 and further characterized by the shedding of the extracellular domain of HER2 [60] . In prostate cancer, PSA secretion was used for CTC detection and secretion of fibroblast growth factor 2 (FGF2) identified a potential stem cell subset of CTCs [52, 61] . In colon cancer, the release of CK19 was also used for CTC detection; interestingly, mesenteric vein blood harbored significantly more CTCs than the peripheral blood supporting the view that the liver filters colon cancer cells [62] . The use of improved EPI-SPOT technologies for future drug testing can be envisaged.
Conclusions and perspectives
Despite many clinical validation studies on thousands of cancer patients [1] , CTCs have not been included yet into the clinical guidelines (e.g., ASCO guidelines at http://www.asco.org/practice-guidelines/ quality-guidelines/guidelines). Although CTC enumeration can improve current tumor staging, the key question remains to be addressed in interventional studies: what is the clinical utility (i.e., its capacity to make a decision possible to adopt or to reject a therapeutic action) of CTCs? Sequential CTC enumeration has been shown in a large multicenter prognostic study to be superior to conventional serum protein markers (CA-15-3, CEA) for early detection of therapy failure in MBC [63] . Thus, in the SWOG 0500 (NCT00382018) interventional trial, MBC patients were randomized between continuation of the first-line chemotherapy (until classic evidence of clinical or radiological progression) or to early switch to another chemotherapy regimen, before any radiological progression [64] . Although the strong prognostic significance of CTCs was confirmed, the CTC-driven switch to another chemotherapy regimen was inefficient [65] . The caveat of interventional biomarker-driven studies is the fact that the diagnostic test is "taken hostage" by the efficacy of the therapy applied, that is, this strategy can only work if there is an efficient therapy for the cohort identified by the test. Thus, there is a need to assess CTC-driven therapy decisions in the context of more efficient therapies that have a beneficial impact on progression-free or overall survival of treated patients. A promising approach is the stratification of MBC patients to chemotherapy or hormonal therapy based on CTC enumeration in the ongoing STIC CTC METABREAST clinical trial (NCT0 1710605) [64] .
Besides CTC enumeration, stratification based on phenotyping of CTCs might become an important strategy. Here, HER2 and ER are the prime target of ongoing interventional trials on BRCA patients [64] . Stratification of MBC patients HER2-targeted therapy based on HER2 status of CTCs is currently tested in the DETECT-III trial [64] .
To introduce CTC tests into clinical trials, an intense validation of the technical aspects of the applied assays is essential, which is currently executed in Europe by the EU-funded CANCER-ID network (www.cancer-id.eu). Characterization of CTCs at the single-cell level require assays with a sufficient capture rate to encompass the intrapatient heterogeneity of CTCs. Low number (or even absence) of CTCs can weaken the reliability of CTC-based assessment of predictive biomarkers in some patients with current detection techniques, which points to the need for further technological advances.
Analysis of single CTCs has the potential to reveal important information for a better understanding of mechanisms of resistance to cancer therapy. For example, ER (À) CTCs may escape endocrine therapy and may therefore represent a minor resistant clone in the beginning of therapy which might subsequently become dominant during treatment. Thus, sequential evaluation of blood samples during the course of therapy might give profound insight into the biology of cancer progression. 
